Key Takeaways
- AI is transforming biotechnology by accelerating drug discovery, enabling precision medicine, and reducing R&D costs.
- The U.S. AI‑in‑biotech market was valued at USD 1.34 billion in 2025 and is projected to reach USD 6.98 billion by 2035 (CAGR 17.90 %).
- Globally, the market is expected to grow from USD 3.91 billion in 2025 to USD 22.50 billion by 2035 (CAGR 19.13 %).
- Key drivers include expanding biological data sets, advances in machine‑learning/deep‑learning, and heightened investment from pharma and biotech firms.
- Leading players—NVIDIA, Illumina, Recursion Pharmaceuticals, Insilico Medicine, and AstraZeneca—are leveraging AI platforms, collaborations, and large‑scale data initiatives to shape the sector’s future.
Overview of AI’s Impact on Biotechnology
Artificial intelligence is reshaping the biotechnology landscape by improving drug discovery, enabling sophisticated biological data analytics, advancing precision medicine, and enhancing biomarker detection. AI‑based systems can process complex biological datasets, identify viable drug targets, predict molecular interactions, and provide data‑driven insights that streamline decision‑making throughout the development pipeline. As one industry observer noted, “AI-based systems are capable of handling complex biological datasets, finding viable drug targets, predicting molecular interactions, and helping scientists make decisions using data-driven insights in drug development processes.” This capability is shortening timelines and lowering the attrition rate that has historically plagued pharmaceutical R&D.
Market Size and Growth Projections
According to SNS Insider, the U.S. Artificial Intelligence (AI) in Biotechnology Market was valued at USD 1.34 billion in 2025 and is expected to reach USD 6.98 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.90 % from 2026 to 2035. On a global scale, the AI‑in‑biotech market stood at USD 3.91 billion in 2025 and is projected to climb to USD 22.50 billion by 2035, reflecting a CAGR of 19.13 % during the same period. These figures underscore the rapid commercial adoption of AI technologies across the biotech value chain, driven by both public and private sector investments.
Drivers Behind AI Adoption in Biotech
Several factors are propelling the integration of AI into biotechnology. The explosion of biological data—spanning genomics, proteomics, metabolomics, and clinical records—provides the raw material needed for training sophisticated machine‑learning models. Concurrently, breakthroughs in deep‑learning algorithms and affordable high‑performance computing have made it feasible to extract actionable patterns from these massive datasets. Pharmaceutical and biotech firms are increasing their AI budgets to cut R&D expenses, improve candidate selection, optimize clinical trial designs, and shorten time‑to‑market. As the source material states, “Availability of biological data sets, advances in machine learning and deep learning, and increased funding by pharmaceutical and biotech companies are making the process of AI incorporation into biotechnology processes faster.”
U.S. Market Leadership and Ecosystem
The United States remains the leading national market for AI in biotechnology, owing to its robust R&D spending in pharma and biotech, advanced healthcare infrastructure, and a vibrant ecosystem that brings together pharmaceutical companies, biotech startups, technology firms, academic research centers, and contract research organizations. This concentration fosters rapid technology transfer and collaborative innovation. The U.S. benefits from early access to cutting‑edge AI hardware and software platforms, enabling firms to deploy AI‑driven drug discovery pipelines at scale. Consequently, American entities are often first to market with AI‑enabled therapeutics and diagnostics, reinforcing the country’s competitive edge.
NVIDIA Corporation: Powering AI‑Driven Biotech
NVIDIA functions as a critical technological enabler for AI‑based biotech and drug discovery, leveraging its GPU‑accelerated computing platforms and AI‑specific technologies. The company’s CUDA‑X microservices for biology, chemistry, and genomics are designed to support drug discovery, generative biology, imaging, and molecular simulations. In 2025, NVIDIA partnered with Eli Lilly to launch a billion‑dollar AI co‑innovation laboratory that integrates AI models, laboratory robotics, and experimental workflows to accelerate molecule discovery and clinical development. As highlighted in the source, “In 2025, NVIDIA, in collaboration with Eli Lilly, initiated an AI co‑innovation laboratory worth a billion dollars that aims at leveraging AI models, robotics in laboratories, and experiments to expedite the discovery and clinical development of molecules.”
Illumina Inc.: Genomics at Scale with the Billion Cell Atlas
Illumina, a dominant force in genomics, is expanding its AI applications to harness the vast data generated by sequencing and cellular studies. In 2026, Illumina inaugurated the Billion Cell Atlas project, aiming to map one billion cells edited with CRISPR to create a comprehensive reference for training AI models in drug discovery. The initiative encourages collaboration with major pharmaceutical partners such as AstraZeneca, Merck, and Eli Lilly, focusing on elucidating disease mechanisms and validating therapeutic targets. The original text notes, “In 2026, Illumina started the project called Billion Cell Atlas, which included the mapping of 1 billion cells modified with the help of CRISPR to use the information for AI model training in drug discovery.”
Recursion Pharmaceuticals: AI‑Enabled Drug Discovery Platform
Recursion Pharmaceuticals employs an AI‑centric approach that combines machine learning, automation, and large‑scale biological data visualization to identify drug candidates. Its technology platform analyzes complex biological relationships to uncover therapeutic implications. In 2024, Recursion strengthened its end‑to‑end drug discovery capabilities through a partnership with Exscientia, integrating AI models, clinical pipelines, automation, and extensive biological datasets. This collaboration exemplifies how AI‑driven platforms can enhance both target identification and lead‑optimization stages, thereby increasing the probability of clinical success.
Insilico Medicine: Generative AI for Target Identification
Insilico Medicine is renowned for its AI‑based computational chemistry platform that supports target identification, molecule generation, and other early‑stage drug development steps. By applying generative adversarial networks and reinforcement learning, the company can propose novel chemical structures with desired pharmacological profiles while predicting synthesis feasibility and safety. The source observes, “This technology by Insilico Medicine is indicative of the increasing use of generative AI and machine learning technologies in drug research, especially as researchers try to enhance their productivity and reduce costs incurred using traditional methods of drug discovery.” Such advances are poised to make early‑stage discovery faster and less resource‑intensive.
AstraZeneca plc: Integrating AI Across Drug Discovery and Precision Medicine
AstraZeneca stands out as a major pharmaceutical player that embeds AI throughout its R&D workflow, spanning drug discovery, genomics, and precision medicine. The firm actively participates in collaborative AI initiatives, most notably the Billion Cell Atlas project alongside Illumina, which aims to decode disease mechanisms and validate therapeutic targets through AI‑assisted analysis of massive cellular datasets. AstraZeneca’s strategy reflects a broader industry shift: leveraging computational technologies to enhance target validation, biomarker discovery, and patient stratification, ultimately delivering more effective, personalized therapies.
Future Outlook: Opportunities and Challenges
Looking ahead, the AI‑in‑biotech market is set to benefit from continued acceleration of drug discovery processes and substantial cost reductions. AI systems will increasingly analyze biological datasets, pinpoint novel drug targets, forecast molecular activity, and refine lead compounds, thereby shortening preclinical timelines. Precision medicine will also expand, as AI integrates genomic data, patient histories, biomarkers, and clinical phenotypes to tailor therapies to individual patients. However, challenges remain, including data privacy concerns, the need for standardized AI validation frameworks, and ensuring equitable access to AI‑driven innovations across global health systems. Addressing these issues will be critical to fully realizing the transformative potential articulated in the source: “With further advancement in genomics and biomarkers studies, AI is likely to play an increasingly important role in these spheres.”
https://www.snsinsider.com/blogs/artificial-intelligence-ai-in-biotechnology-industry